{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:42:38Z","timestamp":1789951358656,"version":"4.0.1"},"reference-count":31,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,10,25]]},"published-print":{"date-parts":[[2017,4]]},"abstract":"\n Objectives<\/jats:title>\n To summarise evidence on temporary discontinuation of medications to prevent acute kidney injury (AKI).<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Systematic review and meta-analysis of randomised and non-randomised studies.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Adults taking diuretics, ACE inhibitors (ACEI), angiotensin receptor blockers (ARB), direct renin inhibitors, non-steroidal anti-inflammatories, metformin or sulfonylureas, experiencing intercurrent illnesses, radiological or surgical procedures.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Temporary discontinuation of any of the medications of interest.<\/jats:p>\n <\/jats:sec>\n \n Primary and secondary outcome measures<\/jats:title>\n Risk of AKI. Secondary outcome measures were estimated glomerular filtration rate and creatinine post-AKI, urea, systolic and diastolic blood pressure, death, clinical outcomes and biomarkers.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n 6 studies were included (1663 participants), 3 randomised controlled trials (RCTs) and 3 prospective cohort studies. The mean age ranged from 65 to 73\u2005years, and the proportion of women ranged from 31% to 52%. All studies were in hospital settings; 5 evaluated discontinuation of medication prior to coronary angiography and 1 prior to cardiac surgery. 5 studies evaluated discontinuation of ACEI and ARBs and 1 small cohort study looked at discontinuation of non-steroidal anti-inflammatory drugs. No studies evaluated discontinuation of medication in the community following an acute intercurrent illness. There was an increased risk of AKI of around 15% in those in whom medication was continued compared with those in whom it was discontinued (relative risk (RR) 1.17, 95% CI 0.99 to 1.38; 5 studies). When only results from RCTs were pooled, the increase in risk was almost 50% (RR 1.48, 95% CI 0.84 to 2.60; 3 RCTs), but the CI was wider. There was no difference between groups for any secondary outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n There is low-quality evidence that withdrawal of ACEI\/ARBs prior to coronary angiography and cardiac surgery may reduce the incidence of AKI. There is no evidence of the impact of drug cessation interventions on AKI incidence during intercurrent illness in primary or secondary care.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n PROSPERO CRD42015023210.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-012674","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T20:10:33Z","timestamp":1491595833000},"page":"e012674","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":84,"title":["What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis"],"prefix":"10.1136","volume":"7","author":[{"given":"Penny","family":"Whiting","sequence":"first","affiliation":[{"name":"The National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West) at University Hospitals Bristol NHS Foundation Trust, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Morden","sequence":"additional","affiliation":[{"name":"The National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West) at University Hospitals Bristol NHS Foundation Trust, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"UK Renal Registry, Bristol, UK"},{"name":"Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus","family":"Caskey","sequence":"additional","affiliation":[{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"},{"name":"UK Renal Registry, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Blakeman","sequence":"additional","affiliation":[{"name":"Centre for Primary Care, Institute of Population Health, The University of Manchester, Manchester, UK"},{"name":"National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) Greater Manchester, Centre for Primary Care, Institute of Population Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Tomson","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Freeman Hospital, Newcastle Upon Tyne Hospitals Foundation Trust, Tyne and Wear, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Stone","sequence":"additional","affiliation":[{"name":"The National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West) at University Hospitals Bristol NHS Foundation Trust, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Richards","sequence":"additional","affiliation":[{"name":"The National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West) at University Hospitals Bristol NHS Foundation Trust, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Savovi\u0107","sequence":"additional","affiliation":[{"name":"The National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West) at University Hospitals Bristol NHS Foundation Trust, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Horwood","sequence":"additional","affiliation":[{"name":"The National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West) at University Hospitals Bristol NHS Foundation Trust, Bristol, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"2025121409205703000_7.4.e012674.1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004090740"},{"key":"2025121409205703000_7.4.e012674.2","unstructured":"National Confidential Enquiry into Patient Outcome and Death. Acute Kidney Injury: Adding Insult to Injury. 2009. http:\/\/www.ncepod.org.uk\/2009aki.html"},{"key":"2025121409205703000_7.4.e012674.3","unstructured":"Think Kidneys. Acute Kidney Injury: the NHS campaign to improve the care of people at risk of, or with, acute kidney injury. 2016. (11 April 2016). https:\/\/www.thinkkidneys.nhs.uk\/aki\/"},{"key":"2025121409205703000_7.4.e012674.4","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318168e375"},{"key":"2025121409205703000_7.4.e012674.5","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2013.109"},{"key":"2025121409205703000_7.4.e012674.6","unstructured":"National Institute for Health and Clinical Excellence. Acute kidney injury: prevention, detection and management. NICE guideline (CG169), 2013."},{"key":"2025121409205703000_7.4.e012674.7","unstructured":"Scottish Patient Safety Programme. Medicine Sick Day Rules Card. 2015. http:\/\/www.scottishpatientsafetyprogramme.scot.nhs.uk\/programmes\/primary-care\/medicine-sick-day-rules-card"},{"key":"2025121409205703000_7.4.e012674.8","unstructured":"Griffith K Ashley C , Blakeman T , et al . \u2018Sick day rules\u2019 in patients at risk of Acute Kidney Injury: an Interim Position Statement from the Think Kidneys Board. 2015. http:\/\/www.thinkkidneys.nhs.uk\/wp-content\/uploads\/2015\/07\/Think-Kidneys-Sick-Day-Rules-160715.pdf"},{"key":"2025121409205703000_7.4.e012674.9","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care [Internet]. 2009. http:\/\/www.york.ac.uk\/inst\/crd\/SysRev\/!SSL!\/WebHelp\/SysRev3.htm"},{"key":"2025121409205703000_7.4.e012674.10","unstructured":"Higgins JPT , Green S. Cochrane handbook for systematic reviews of interventions [Internet]. 2011. http:\/\/www.cochrane-handbook.org\/"},{"key":"2025121409205703000_7.4.e012674.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2025121409205703000_7.4.e012674.12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13643-015-0135-y","article-title":"The risks and benefits of patients temporarily discontinuing medications in the event of an intercurrent illness: a systematic review protocol","volume":"4","author":"Morden","year":"2015","journal-title":"Syst Rev"},{"key":"2025121409205703000_7.4.e012674.13","unstructured":"Savovic J , Higgins J , Sterne J , et al . Introducing a revised risk of bias tool for randomized trials. Cochrane Colloquium, 2015. http:\/\/www.cochranelibrary.com\/dotAsset\/5bc8d6fd-0604-4bed-beb2-8bc7a74aa4b9.pdf"},{"key":"2025121409205703000_7.4.e012674.14","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne Jonathan","year":"2016","journal-title":"BMJ"},{"key":"2025121409205703000_7.4.e012674.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025121409205703000_7.4.e012674.16","first-page":"682","article-title":"Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study","volume":"15","author":"Wolak","year":"2013","journal-title":"Isr Med Assoc J"},{"key":"2025121409205703000_7.4.e012674.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-008-9368-1"},{"key":"2025121409205703000_7.4.e012674.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.04.019"},{"key":"2025121409205703000_7.4.e012674.19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft405"},{"key":"2025121409205703000_7.4.e012674.20","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.12.1325"},{"key":"2025121409205703000_7.4.e012674.21","first-page":"642","article-title":"Effects of renin-angiotensin-aldosterone system blockers on contrast-induced nephropathy and its association with NGAL levels in diabetic patients undergoing coronary angiography","volume":"36","author":"Goksuluk","year":"2015","journal-title":"Eur Heart J"},{"key":"2025121409205703000_7.4.e012674.22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrneph.2013.80","article-title":"Three feasible strategies to minimize kidney injury in \u2018incipient AKI","volume":"9","author":"Perazella","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025121409205703000_7.4.e012674.23","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.5.685"},{"key":"2025121409205703000_7.4.e012674.24","first-page":"92","article-title":"Medicine sick day rules cards: a safe and effective tool to improve medicines safety in NHS Highland","volume":"23","author":"Morrison","year":"2015","journal-title":"Int J Pharm Pract"},{"key":"2025121409205703000_7.4.e012674.25","unstructured":"Canadian Diabetes Association. Sick Day Medication List. 2015. http:\/\/guidelines.diabetes.ca\/browse\/appendices\/appendix7_2015"},{"key":"2025121409205703000_7.4.e012674.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62459-4"},{"key":"2025121409205703000_7.4.e012674.27","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.101"},{"key":"2025121409205703000_7.4.e012674.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8525"},{"key":"2025121409205703000_7.4.e012674.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.0306-5251.2004.2188.x"},{"key":"2025121409205703000_7.4.e012674.30","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05271107"},{"key":"2025121409205703000_7.4.e012674.31","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05480610"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-012674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:21:03Z","timestamp":1765732863000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-012674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,7]]},"published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1136\/bmjopen-2016-012674"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-012674","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}